Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis

Yasuhito Hamaguchi(Kanazawa University), Masataka Kuwana(Keio University), Kana Hoshino(Keio University), Minoru Hasegawa(Kanazawa University), Kenzo Kaji(Kanazawa University), Takashi Matsushita(Kanazawa University), Kazuhiro Komura(Kanazawa University), Motonobu Nakamura(University of Occupational and Environmental Health Japan), Masanari Kodera(Japan Community Healthcare Organization), Norihiro Suga(Aichi Medical University), Akira Higashi(Red Cross Hospital), Koji Ogusu(University Dermatology), Kiyohiro Tsutsui(Ishikawa Prefectural Central Hospital), Akira Furusaki(Sapporo City General Hospital), Hiroshi Tanabe(Kanazawa Medical University), Shunsuke Sasaoka(Kawasaki Medical School), Yoshinao Muro(Nagoya University), Mika Yoshikawa(Ōtani University), Naoko Ishiguro(Tokyo Women's Medical University), Masahiro Ayano(Kurashiki Central Hospital), Eiji Muroi(Nagasaki University), Keita Fujikawa(Nagasaki University), Yukihiro Umeda(University of Fukui), Masaaki Kawase(Jikei University School of Medicine), Eriko Mabuchi(Japan Community Healthcare Organization), Yoshihide Asano(The University of Tokyo), Kinuyo Sodemoto(NTT (United States)), Mariko Seishima(Ogaki Municipal Hospital), Hidehiro Yamada(St. Marianna University School of Medicine), Shinichi Sato(The University of Tokyo), Kazuhiko Takehara(Kanazawa University), Manabu Fujimoto(Kanazawa University)
Archives of Dermatology
April 11, 2011
Cited by 330

Abstract

OBJECTIVE: To clarify the association of clinical and prognostic features with dermatomyositis (DM)-specific autoantibodies (Abs) in adult Japanese patients with DM. DESIGN: Retrospective study. SETTING: Kanazawa University Graduate School of Medical Science Department of Dermatology and collaborating medical centers. Patients A total of 376 consecutive adult Japanese patients with DM who visited our hospital or collaborating medical centers between 2003 and 2008. MAIN OUTCOME MEASURES: Clinical and laboratory characteristics of adult Japanese patients with DM and DM-specific Abs that include Abs against Mi-2, 155/140, and CADM-140. RESULTS: In patients with DM, anti-Mi-2, anti-155/140, and anti-CADM-140 were detected in 9 (2%), 25 (7%), and 43 (11%), respectively. These DM-specific Abs were mutually exclusive and were detected in none of 34 patients with polymyositis, 326 with systemic sclerosis, and 97 with systemic lupus erythematosus. Anti-Mi-2 was associated with classical DM without interstitial lung disease or malignancy, whereas anti-155/140 was associated with malignancy. Patients with anti-CADM-140 frequently had clinically amyopathic DM and rapidly progressive interstitial lung disease. Cumulative survival rates were more favorable in patients with anti-Mi-2 compared with those with anti-155/140 or anti-CADM-140 (P < .01 for both comparisons). Nearly all deaths occurred within 1 year after diagnosis in patients with anti-CADM-140. Conclusion Dermatomyositis-specific Abs define clinically distinct subsets and are useful for predicting clinical outcomes in patients with DM.


Related Papers

No related papers found

Powered by citation graph analysis